{"paper_id":"e833e17e-bbf8-4d6b-b872-eb7500b587e6","body_text":"18.03.2025\nLinzagolix for endometriosis: comparative data are lacking\nFor endometriosis, there are no comparative studies with established drugs. Placebo comparisons are unsuitable for assessing the added benefit.\nPress release\nLast updated 17.03.2025\nProject no.:\nA24-123\nCommission:\nCommission awarded on 16.12.2024 by the Federal Joint Committee (G-BA).\nReport type:\nDossier assessment\nStatus:\nCommission completed\nDepartment/Division:\nDrug Assessment\nTopic:\nReproductive health and birth\nIndication:\nSymptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis; with concomitant hormonal add-back therapy\nResult of dossier assessment:\nAdded benefit not proven\nNote:\nAfter completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.\nDOI:\nhttps://doi.org/10.60584/A24-123_en\n18.03.2025\nFor endometriosis, there are no comparative studies with established drugs. Placebo comparisons are unsuitable for assessing the added benefit.\nPress release\n-\nExtract of dossier assessment: Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V\nDOI:\nhttps://doi.org/10.60584/A24-123_en\nEN, PDF, 244 kB, PDFpublished on Mar 17, 2025\n-\nDossier assessment: Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V\nDOI:\nhttps://doi.org/10.60584/A24-123\nDE, PDF, 423 kB, PDFpublished on Mar 17, 2025\n| Project no. | Title | Status |\n|---|---|---|\n| A24-92 | Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V | Commission completed |","source_license":"CC0","license_restricted":false}